Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-186-5 | CAS number: 53-86-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Additional toxicological data
Administrative data
- Endpoint:
- additional toxicological information
- Adequacy of study:
- other information
Data source
Referenceopen allclose all
- Reference Type:
- other: FDA approved label document
- Title:
- Label for Indocin(R) -Indomethacin (Oral Suspension) by IROKO Pharmaceuticals, LLC
- Year:
- 2 009
- Bibliographic source:
- Pharmapendium(TM), Elsevier, Inc.
- Reference Type:
- other: FDA Approval Package
- Title:
- New Drug Application (NDA) 018332
- Year:
- 1 980
- Bibliographic source:
- Pharmapendium (TM) by Elsevier, Inc.
- Reference Type:
- other: FDA approval package
- Title:
- NDA 018858
- Year:
- 1 982
- Bibliographic source:
- Pharmapendium(TM) by Elsevier, Inc.
- Reference Type:
- other: FDA approval package
- Title:
- NDA 018878
- Year:
- 1 983
- Bibliographic source:
- Pharmapendium(TM) by Elsevier, Inc.
- Reference Type:
- other: FDA approval package
- Title:
- NDA 018730
- Year:
- 1 984
- Bibliographic source:
- Pharmapendium(TM) by Elsevier, Inc.
- Reference Type:
- other: FDA approval package
- Title:
- NDA 018185
- Year:
- 1 989
- Bibliographic source:
- Pharmapendium(TM) by Elsevier, Inc.
Materials and methods
Results and discussion
Any other information on results incl. tables
A comprehensive evaluation of indomethacin is available from U.S. Food & Drug Administration (www.pharmapendium.com). Based on that the following informations are given:
Indocin(R) is a drug formulation containing indomethacin as the active ingredient. Total daily doses are between 150 - 200 mg/Patient, divided in 3 - 4 dosages/day.
Indomethacin belongs to the class of non-steroidal anti-inflammatory drugs (NSAIDs) with antipyretic, anti-inflammatory and analgesic properties. It is a potent prostaglandin synthesis inhibito in vitro and is therapeutically used in different formulations for different indications comprising long-term treatment of rheumatoid arthritis, ankylosing spondylitis, and osteoarthritis as well as more acute indications like painful shoulder and acute gouty arthritis. In neonatal infants indomethacin is used for treatment of persistent ductus arteriosus.
Use of indomethacin is contraindicated in patients with known hypersensitivity, in patients who have experienced asthma, urticaria, or allergic-tpye reactions after taking aspirin or other NSAIDs and for treatment of peri-operative pain in patients with coronary artery bypass graft surgery. Warnings are given with respect to cardiovascular thrombotic events, onset or worsening of hypertension, congestive heart failure and edema, gastrointestinal effects (risk of ulceration, bleeding, perforation), renal effects and kidney disease (papillary necrosis, renal injury, decreased prostaglandin-mediated renal blood flow), hyperkalemia, anaphylaxis, anaphylactoid reactions, skin reactions (exfoliative dermatitis, Steven-Johnson-Syndrom, toxic epidermal necrolysis), ocular and central nervous effects. Anemia (in relation to fluid retention or gastrointestinal blood loss, effects on erythropoesis) and inhibition of platelet aggregation (reversible) may occur. Increase of liver enzymes (ALT/AST) and rare cases of jaundice, fatal fulminant hepatitis, liver necrosis and heptaic failure have been reported. In pregnancy Indomethacin should be avoided due to the risk of premature closure of the ductus arteriosus.
Unwanted effects during drug therapy affects with the highest incidence (> 1%) the gastrointestinal system (nausea, vomiting, dyspepsia, diarrhea, constipation, pain), the central nervous system (headache, dizziness, vertigo, somnolence, depression and fatigue) and tinnitus.
The toxicity studies of indomethacin comprised acute, subacute and chronic toxicity studies in mice, rats, guinea pigs, rabbits, cats, dogs, monkeys, domestic pigs and chickens. Chronic toxicity studies were performed in dogs (up to 129 weeks), rats (up to 52 weeks), monkeys (18 weeks), rabbits (22 weeks) and guinea pigs (27 weeks). Men tolerated indomethacin better than experimental animals (especially than dogs and rats). The most observed toxic effect of Indomethacin i.e. gastric ulceration occurred within 2 weeks when more than 5 mg/kg bw was administered. Besides the GI tract, kidney and liver toxicities were the most frequent effects. In the chronic toxicity studies, cellular infiltration of kidney and liver in rats, and renal amyloidosis and papillary necrosis in mice were observed at dose levels of 2 -5 mg/kg/day. The carcinogenicity study in rats and mice revealed no tumorigenic effect (dose levels: 0.5, 1.0 and 2.0 (later decreased 1.5 due to high mortality) mg/kg/day.
In reproductive toxicity studies in rats and mice (dosages of 0.5,1, 2 and 4 mg/kg/day) , teratogenicity was not observed up to 4 mg/kg/day. Retarded fetal ossification was secondary to reduced fetal weights. Maternal toxicity, increased prenatal loss (resorptions) and malformations were reported at higher doses (5 -15 mg/kg/day) in mice. Indomethacin delayed parturition in rats, and caused an increase of neuronal necrosis in the brain (diencephalon) of newborn rats when given at a dose of 4 mg/kg/day for the last 3 days before parturition. This effect was not evident when the identical dose was given to newborn rats on the first 3 days of life.
In rat studies with NSAIDs dystocias, delayed parturition, decreased pup survival occurred.
Effects of Indomethacin and other drugs of this class when given during the 3rd trimester on the human fetus include constriction of the ductus arteriosus prenatally, incompetence of tricuspidal incompetence, pulmonary hyertension, non-closure of the ductus arteriosus postnatally, myocardial degenerativ changes, platelet dysfunction with resultant bleeding, intracranial bleeding, renal disfunction of failure, renal injura/dysgenesis, oligohydramnios, gastrointestinal bleeding or perforation, increased risk of necrotizing enterocolitis.
The acute oral LD50 of Indomethacin base in female mice was 849 mg/kg based on 24 hour mortality and 50 mg/kg based on 14 -day mortality (GI toxicity), the oral LD50 for rats was 12 mg/kg; in newborn (24- 72 hours old) rats oral LD50 was 44 mg/kg ; LD50 after intravenous administration in Beagle pups appears to be > 81 mg/kg.
Indomethacin passes the placenta (Clinical Pharmacokin. 6, 245 -258, 1981) and is transfered into milk (Am J. Hosp. Pharm. 31, 844 -854, 1974). Intravasal administration of 0.1 ml/kg of an 25 mg/mL solution (1%) was not irritant to arteries and veins (of rats?).
Pharmacokinetic investigation in humans revealed 100% protein-binding (90% to albumin), entero-hepatic circulation, high bioavailability after oral and rectal administration (about 100%), elimination after oral administration via urine (~ as conjugated parent drug (23% of total) and non-conjugated metabolites) and bile/feces (~40%), half-life time of 5 -10 hours, and maximum plasma concentration after ~2 hours. Metabolites in adults are desmethyl-, desbenzoyl- and desmethyl-desbenzoyl- Indomethacin.
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.